Zobrazeno 1 - 10
of 383
pro vyhledávání: ''
Autor:
Aaron H. Wolfson, Omar Ragab, Anne F. Rositch, Amanda Nickles Fader, David Miller, Warner K. Huh, Steven E. Waggoner, Kimberly Levinson, Nicola M. Spirtos, Laura L. Holman, Leah McNally, Saketh R. Guntupalli, Yi-Chun Lee, Krishnansu S. Tewari, Yovanni Casablanca, Kelly Jeanes Wilkinson, Anna Beavis, Michael Kelly, Linda Van Le, Akila N. Viswanathan, Christopher Purdy
Publikováno v:
Gynecol Oncol
Purpose The Sedlis criteria define risk factors for recurrence warranting post-hysterectomy radiation for early-stage cervical cancer; however, these factors were defined for squamous cell carcinoma (SCC) at an estimated recurrence risk of ≥30%. Ou
Autor:
Yongmei Huang, Rebecca A. Previs, Alexander Melamed, Benjamin B. Albright, Jason D. Wright, M.S. Dawn L. Hershman, Grace Clarke Hillyer
Publikováno v:
Gynecol Oncol
Objective Neoadjuvant chemotherapy (NACT) has emerged as an alternative to primary cytoreductive surgery (PCS) for stage IV uterine cancer. We examined utilization, perioperative outcomes and survival for NACT and PCS for stage IV uterine cancer. Met
Autor:
Mario M. Leitao, Nadeem R. Abu-Rustum, Anoushka M. Afonso, William A. Zammarrelli, Jennifer J. Mueller, Amelia Chan, Vance Broach, Oliver Zivanovic, Yukio Sonoda
Publikováno v:
Gynecol Oncol
Objective To describe the incidence of adverse reactions to indocyanine green (ICG) administered during sentinel lymph node (SLN) biopsy for endometrial cancer, and to propose an ICG management algorithm for these patients. Methods All patients who u
Autor:
Stephanie V. Blank, Ravi Sharaf, Steven M. Lipkin, Julia Feit, Paul J. Christos, Jenny Lin, Kevin Holcomb, Kenneth Offit, Charlene Thomas, Drew Wright, Hannah Bergeron, Danyal Ahsan, Melissa K. Frey, Rachel Saganty, Evelyn Cantillo, Andrea Khoury, Eloise Chapman-Davis, Ying Liu
Publikováno v:
Gynecol Oncol
Purpose Several professional organizations recommend universal genetic assessment for people with ovarian cancer as identifying pathogenic variants can affect treatment, prognosis, and all-cause mortality for patients and relatives. We sought to eval
Autor:
Dineo Khabele, Katherine F. Roby, Alessandro Vindigni, Helen Zhou, Andrew J. Wilson, Makena L. Clive, Shariska Petersen, Marta A. Crispens, Jeff Hirst, Vijayalaxmi Gupta, Katherine Fuh, Harsh B. Pathak, Andrea Jewell, Meghan Kusch, Andrew K. Godwin, Emily Cybulla
Publikováno v:
Gynecol Oncol
Objective Poly ADP ribose polymerase inhibitors (PARPi) are most effective in BRCA1/2 mutated ovarian tumors. Better treatments are needed for homologous recombination HR-proficient cancer, including CCNE1 amplified subtypes. We have shown that histo
Autor:
Robert L. Coleman, Nicole D. Fleming, Aaron Shafer, Anil K. Sood, Pamela T. Soliman, Lauren P. Cobb, J. Alejandro Rauh-Hain, Shannon N. Westin, Amir A. Jazaeri, Bryan Fellman, Karen H. Lu, Larissa A. Meyer
Publikováno v:
Gynecol Oncol
OBJECTIVES: To evaluate the factors associated with response to neoadjuvant chemotherapy (NACT) and the ability to undergo interval tumor reductive surgery (iTRS) in patients with advanced ovarian cancer. METHODS: We performed a retrospective review
Autor:
Megan Mullins, Michele L. Cote, Shitanshu Uppal, Lauren P. Wallner, Julie J. Ruterbusch, Philippa Clarke
Publikováno v:
Gynecol Oncol
Objective To evaluate the association between post-diagnosis continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer. Methods This retrospective claims analysis included 6680 Medicare beneficiaries over age 6
Autor:
Bryan Fellman, Nicole D. Fleming, Roni Nitecki, J. Alejandro Rauh-Hain, Karen H. Lu, Larissa A. Meyer, Anil K. Sood
Publikováno v:
Gynecol Oncol
Objective The ideal number of neoadjuvant chemotherapy (NACT) cycles prior to interval tumor-reductive surgery (iTRS) for advanced ovarian cancer is poorly defined. We sought to assess survival stratified by number of NACT cycles and residual disease
Autor:
Mark A. Fiala, Matthew A. Powell, Tanya M. Wildes, Andrea R. Hagemann, Tyler McKinnish, Lindsay M. Kuroki, Carolyn K. McCourt, Katherine Fuh, Premal H. Thaker, Abigail S. Zamorano, David G. Mutch, Mary M. Mullen
Publikováno v:
Gynecol Oncol
OBJECTIVE. To determine the association between scores from a 25-item patient-reported Rockwood Accumulation of Deficits Frailty Index (DAFI) and survival outcomes in gynecologic cancer patients. METHODS. A frailty index was constructed from the SEER
Autor:
Andrew J. Vickers, Joanne Alonso, William P. Tew, Kara Long Roche, Dennis S. Chi, Olga T. Filippova, Oliver Zivanovic, Ginger J. Gardner, Armin Shahrokni, Amy Tin, Yukio Sonoda
Publikováno v:
Gynecol Oncol
OBJECTIVES: To determine whether the Memorial Sloan Kettering Frailty Index (MSK-FI) is associated with decision-making in older women surgically treated for advanced-stage ovarian cancer. METHODS: We retrospectively applied the MSK-FI to women ≥70